Evidence map›Paper›PMID 41288966›Full record

ArticleActa paediatrica (Oslo, Norway : 1992)2026

Population-Based Cohort Study for Development of National Retinopathy of Prematurity Screening Criteria.

R Gerull, C Sanchez, A Atkinson, M Schuler-Barazzoni, M Adams, F Barcos Munoz, C Gerth-Kahlert, S M Schulzke, Swiss Neonatal Network

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta paediatrica (Oslo, Norway : 1992), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

R GerullDepartment of Neonatology, University Children's Hospital Basel UKBB, Basel, Switzerland.
C SanchezPediatric Research Centre, University Children's Hospital Basel, University of Basel, Basel, Switzerland.
A AtkinsonPediatric Research Centre, University Children's Hospital Basel, University of Basel, Basel, Switzerland.ORCID 0000-0001-5834-8315
M Schuler-BarazzoniClinic of Neonatology, Department Woman-Mother-Child, University Hospital of Lausanne, Lausanne, Switzerland.
M AdamsDepartment of Neonatology, Newborn Research, University Hospital Zurich (USZ), University of Zurich (UZH), Zurich, Switzerland.
F Barcos MunozNeonatal Intensive Care Unit, University Hospital of Geneva, Geneva, Switzerland.ORCID 0000-0001-7143-6117
C Gerth-KahlertDepartment of Ophthalmology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
S M SchulzkeDepartment of Neonatology, University Children's Hospital Basel UKBB, Basel, Switzerland.
Swiss Neonatal Network

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimScreening criteria for retinopathy of prematurity (ROP) vary among countries. Early detection of ROP and minimising the burden of screening are important.

methodsWe analysed data from very preterm infants born in Switzerland between 2006 and 2022. Logistic regression models were fitted to evaluate 17 potential risk factors for ROP treatment.

results168/11354 patients (median (range) gestational age (GA) 29.6 (23.0-31.9) weeks) required ROP treatment. All would have been detected and screening burden would have been reduced by 56% if screening had required meeting ≥ 1 of the following criteria: GA < 27 weeks (89.3%), birth weight < 1000 g (97.0%), intraventricular haemorrhage≥II° (24.0%), congenital tumour (1.2%). We identified six statistically significant risk factors for ROP: GA (adjusted odds ratio (aOR) 0.46, 95% CI 0.40-0.52, p < 0.001), birth weight z-score (aOR 0.58, 95% CI 0.46-0.73, p < 0.001), duration of supplemental oxygen (aOR 1.01 95% CI 1.01-1.02, p < 0.001), duration of mechanical ventilation (OR 1.01, 95% CI 1.00-1.02, p = 0.018), caesarean section (OR 1.84, 95% CI 1.06-3.36, p = 0.038), and congenital tumour (OR 26.3, 95% CI 2.71-189, p = 0.002). The model allowed for excellent prediction of ROP treatment (AUC 0.963, 95% CI 0.944-0.981).

conclusionsSafely reducing the burden of ROP screening appears achievable in Switzerland.

Indexed as

Neonatal ScreeningRetinopathy of PrematurityCohort StudiesFemaleGestational AgeHumansInfant, NewbornMaleRisk FactorsSwitzerlandpretermretinopathy of prematurityscreening

Identifiers

PMID41288966
PMCPMC12889992

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.